A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 20,964 shares of ARQT stock, worth $314,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,964
Holding current value
$314,250
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.32 - $11.0 $174,420 - $230,604
20,964 New
20,964 $194,000
Q1 2024

May 15, 2024

BUY
$3.25 - $11.77 $665,531 - $2.41 Million
204,779 New
204,779 $2.03 Million
Q3 2023

Nov 15, 2023

BUY
$5.31 - $10.98 $241,397 - $499,161
45,461 New
45,461 $241,000
Q1 2023

May 15, 2023

BUY
$10.23 - $17.14 $310,030 - $519,444
30,306 New
30,306 $333,000
Q3 2022

Nov 14, 2022

BUY
$17.85 - $26.95 $327,529 - $494,505
18,349 New
18,349 $351,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $902M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.